The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Open accessAbstract
OBJECTIVE: A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines. METHODS: We employed Pittsburgh compound B positron emission tomography (PET) imaging as our biomarker of cerebral amyloidosis, and (18) fluorodeoxyglucose PET imaging and hippocampal volume as biomarkers of neurodegeneration. A group of 42 clinically diagnosed AD subjects was used to create imaging biomarker cutpoints. A group of 450 cognitively normal (CN) subjects from a population-based sample was used to develop cognitive cutpoints and to assess population frequencies of the different preclinical AD stages using different cutpoint criteria. RESULTS: The new criteria subdivide the preclinical phase of AD into stages 1 to 3. To classify our CN subjects, 2 additional categories were needed. Stage 0 denotes subjects with normal AD biomarkers and no evidence of subtle cognitive impairment. Suspected non-AD pathophysiology (SNAP) denotes subjects with normal amyloid PET imaging, but abnormal neurodegeneration biomarker studies. At fixed cutpoints corresponding to 90% sensitivity for diagnosing AD and the 10th percentile of CN cognitive scores, 43% of our sample was classified as stage 0, 16% stage 1, 12 % stage 2, 3% stage 3, and 23% SNAP. INTERPRETATION: This cross-sectional evaluation of the NIA-AA criteria for preclinical AD indicates that the 1-3 staging criteria coupled with stage 0 and SNAP categories classify 97% of CN subjects from a population-based sample, leaving only 3% unclassified. Future longitudinal validation of the criteria will be important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial studies in this emerging area have identified subgroups of older adults with subtle cognitive decline that do not conform to expected patterns and investigators have designated them as Suspected Non-Alzheimer Pathology (SNAP) and Unclassified groups [51, 52].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [212]
In the citing paper
“Yet, this finding is in line with recent studies showing that AD-type atrophy and/or hypometabolism can be found in both Aβ-negative healthy controls (Jack et al., 2012) and Aβ-negative MCI patients (Prestia et al., 2013).”
From Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia (2013) · cites this paper as Jack et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 601
Florek, L., Tiepolt, S., Schroeter, M. L., Berrouschot, J., Saur, D., Hesse, S., Jochimsen, T. H., Luthardt, J., Sattler, B., Patt, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180522 · Cited by 28
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 31
Huang, Y., Ma, Y., Gao, P., Wang, Z., Huang, L., Hou, J., Tan, L., & Yu, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01217-6 · Cited by 29
Risk Factors and Screening Methods for Detecting Dementia: A Narrative Review
Stephan, B. C. M., & Brayne, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141413 · Cited by 27
The Role of -Amyloid in Alzheimer's Disease-Related Neurodegeneration
Goldsworthy, M. R., & Vallence, A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2252-13.2013 · Cited by 27
Rawlings, A. M., Bandeen‐Roche, K., Gross, A. L., Gottesman, R. F., Coker, L. H., Penman, A. D., Sharrett, A. R., & Mosley, T. H. (2016) · Psychological Assessment · doi:10.1037/pas0000293 · Cited by 27
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease
Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Nation, D. A., Furst, A. J., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000928 · Cited by 28
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Giau, V. V., Bagyinszky, E., Lim, K., Kang, S. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160143 · Cited by 26
Knopman, D. S., Jack, C. R., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.003 · Cited by 27
Self-citationHaight, T. J., Bryan, R. N., Meirelles, O., Tracy, R. P., Fornage, M., Richard, M. A., Nasrallah, I. M., Yaffe, K. S., Jacobs, D. R., Lewis, C. E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190478 · Cited by 26
Takamiya, A., Casteele, T. V., Koole, M. J. B., Winter, F. D., Bouckaert, F., den Stock, J. V., Sunaert, S. G., Dupont, P. J., Vandenberghe, R. R., Laere, K. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95206-0 · Cited by 27
Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET
Townley, R. A., Botha, H., Graff‐Radford, J., Whitwell, J. L., Boeve, B. F., Machulda, M. M., Fields, J. A., Drubach, D. A., Savica, R., Petersen, R. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab182 · Cited by 25
Self-citationIncident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer’s Disease
Weamer, E. A., DeMichele‐Sweet, M. A. A., Cloonan, Y. K., López, O. L., & Sweet, R. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10617 · Cited by 26
Xing, Y., Wei, P., Wang, C., Shan, Y., Yu, Y., Qiao, Y., Xie, B., Shi, X., Zhu, Z., Lu, J., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12005 · Cited by 25
Baek, H.-I., Ha, K.-C., Park, Y.-K., Kim, T. Y., & Park, S.-J. (2024) · Nutrients · doi:10.3390/nu16121952 · Cited by 28
Gagliardi, G. P., for the INSIGHT-preAD study group, Epelbaum, S., Houot, M., Bakardjian, H., Boukadida, L., Revillon, M., Dubois, B., Barba, G. D., & Corte, V. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180966 · Cited by 25
Shi, D., Xie, S., Li, A., Wang, Q., Guo, H., Han, Y., Xu, H., Gan, W., Zhang, L., Guo, T., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01899-w · Cited by 25
Jacquemont, T., Fallani, F. D. V., Bertrand, A., Epelbaum, S., Routier, A., Dubois, B., Hampel, H. J., Durrleman, S., & Olivier Colliot, A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.023 · Cited by 26
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
Zeydan, B., Lowe, V. J., Reichard, R. R., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Parisi, J. E., Machulda, M. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25684 · Cited by 27
Self-citationRole of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. K. O., & Giau, V. V. (2020) · Diagnostics · doi:10.3390/diagnostics10050326 · Cited by 25
Chronic RNA G-quadruplex accumulation in aging and Alzheimer’s disease
Kallweit, L. M., Hamlett, E. D., Saternos, H., Gilmore, A., Granholm, A., & Horowitz, S. A. (2025) · eLife · doi:10.7554/elife.105446.3 · Cited by 32
Subtle visuomotor difficulties in preclinical A lzheimer's disease
Mollica, M. A., Navarra, J., Fernández‐Prieto, I., Olives, J., Tort‐Merino, A., Valech, N., Coll‐Padrós, N., Molinuevo, J. L., & Rami, L. (2015) · Journal of Neuropsychology · doi:10.1111/jnp.12079 · Cited by 26
The Role of Age on Beta-Amyloid1–42 Plasma Levels in Healthy Subjects
Zecca, C., Pasculli, G., Tortelli, R., Dell’Abate, M. T., Capozzo, R., Barulli, M. R., Barone, R., Accogli, M., Arima, S., Pollice, A., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.698571 · Cited by 26
Schermer, M. (2023) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhad009 · Cited by 26
Mehta, R. S., Kochar, B. D., Zhou, Z., Broder, J. C., Chung, P. E., Yang, K., Lockery, J. E., Fravel, M. A., Ryan, J. L., Mahady, S. E., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.052 · Cited by 26
Mahalingam, S., & Chen, M.-K. (2019) · Seminars in neurology · doi:10.1055/s-0039-1678580 · Cited by 16
Lahr, J., Peter, J., Minkova, L., Lauer, E. M., Reis, J., Heimbach, B., Hüll, M., Normann, C., Nissen, C., & Klöppel, S. (2015) · Clinical Neurophysiology · doi:10.1016/j.clinph.2015.08.010 · Cited by 24
Asih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 24
Corriveau‐Lecavalier, N., Gunter, J. L., Kamykowski, M. G., Dicks, E., Botha, H., Kremers, W. K., Graff‐Radford, J., Wiepert, D. A., Schwarz, C. G., Yacoub, E. S., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad058 · Cited by 23
Self-citationMolecular Imaging of Alzheimer Disease Pathology
Kantarci, K. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3847 · Cited by 24
Self-citationDeciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease
Corriveau‐Lecavalier, N., Barnard, L. R., Lee, J., Dicks, E., Botha, H., Graff‐Radford, J., Machulda, M. M., Boeve, B. F., Knopman, D. S., Lowe, V. J., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad017 · Cited by 25
Self-citationLafirdeen, A. S. M., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217026 · Cited by 24
Smith, R. X., Strain, J. F., Tanenbaum, A., Fagan, A. M., Hassenstab, J. J., McDade, E., Schindler, S. E., Gordon, B. A., Xiong, C., Chhatwal, J. P., et al. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0808 · Cited by 25
Self-citationPreventing cognitive decline in preclinical Alzheimer's disease
Riedel, W. J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.10.002 · Cited by 22
Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia
Eisenmenger, L. B., Huo, E. J., Hoffman, J. M., Minoshima, S., Matesan, M. C., Lewis, D. H., Lopresti, B. J., Mathis, C. A., Okonkwo, D. O., & Mountz, J. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.003 · Cited by 21
Ortega, R. L., Dakterzada, F., Arias, A. M., Blasco, E., Naudí, A., Purroy, F. F., & Piñol‐Ripoll, G. (2019) · Current Aging Science · doi:10.2174/1874609812666190112095430 · Cited by 23
The clinical importance of suspected non-Alzheimer disease pathophysiology
Vos, S. J. B., Delvenne, A., Jack, C. R., Thal, D. R., & Visser, P. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00962-y · Cited by 23
Self-citationModulation of glucose metabolism and metabolic connectivity by β-amyloid
Carbonell, F., Zijdenbos, A. P., McLaren, D. G., Iturria‐Medina, Y., Bedell, B. J., & Initiative, A. D. N. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16654492 · Cited by 22
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
Alexopoulos, P., Werle, L., Roesler, J., Thierjung, N., Gleixner, L. S., Yakushev, I. Y., Laskaris, N., Wagenpfeil, S., Gourzis, P., Kurz, A., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0220-z · Cited by 22
Promise and Challenge: The Lens Model as a Biomarker for Early Diagnosis of Alzheimer's Disease
Tian, T., Zhang, B., Jia, Y., & Li, Z. (2014) · Disease Markers · doi:10.1155/2014/826503 · Cited by 22
Mosconi, L., Nerattini, M., Williams, S., & Fink, M. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf026 · Cited by 26
Kikuchi, M., Kobayashi, K., Itoh, S., Kasuga, K., Miyashita, A., Ikeuchi, T., Yumoto, E., Kosaka, Y., Fushimi, Y., Takeda, T., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.08.007 · Cited by 21
A quantitative neural network approach to understanding aging phenotypes
Ash, J. A., & Rapp, P. R. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.02.001 · Cited by 20
Zhu, Y., Initiative, O. B. O. A. D. N., Gong, L., He, C., Wang, Q., Ren, Q., & Xie, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190254 · Cited by 20
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 20
The interest of amyloid PET imaging in the diagnosis of Alzheimerʼs disease
Vandenberghe, R. R., Adamczuk, K., & Laere, K. V. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000036 · Cited by 20
Electroconvulsive therapy response in late-life depression unaffected by age-related brain changes
Bouckaert, F., Emsell, L., Vansteelandt, K., Winter, F. D., den Stock, J. V., Obbels, J., Dols, A., Stek, M. L., Adamczuk, K., Sunaert, S. G., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.055 · Cited by 20
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Mark, R. E., & Brehmer, Y. (2022) · European Journal of Ageing · doi:10.1007/s10433-022-00735-w · Cited by 20
Fagan, A. M. (2014) · Advances in Geriatrics · doi:10.1155/2014/302712 · Cited by 21
Arendash, G. W., Abulaban, H., Steen, S., Andel, R., Wang, Y., Bai, Y., Baranowski, R., McGarity, J., Scritsmier, L., Lin, X., et al. (2022) · Medicines · doi:10.3390/medicines9080042 · Cited by 21
Down syndrome biobank consortium: a perspective
Aldecoa, I., Barroeta, I., Carroll, S. L., Fortea, J., Gilmore, A., Ginsberg, S. D., Guzman, S. J., Hamlett, E. D., Head, E., Perez, S. E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13692 · Cited by 19
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
The Relationship between Amyloid Deposition, Neurodegeneration, and Cognitive Decline in Dementia
Vandenberghe, R. R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0498-9 · Cited by 21
Yang, Y., Jia, X., Feng, J., Wang, Z., Cao, Y., Liu, J., & Li, H. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/5934254 · Cited by 19
Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration
Wisse, L. E. M., Das, S. R., Davatzikos, C. A., Dickerson, B. C., Xie, S. X., Yushkevich, P. A., & Wolk, D. A. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.02.008 · Cited by 19
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21
Chiaravalloti, A., Barbagallo, G., Martorana, A., Castellano, A. E., Ursini, F., & Schillaci, O. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04379-4 · Cited by 19
Cao, C., Abulaban, H., Baranowski, R., Wang, Y., Bai, Y., Lin, X., Shen, N., Zhang, X., & Arendash, G. W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.829049 · Cited by 20
Does essential tremor increase risk of cognitive impairment and dementia? Yes
Cosentino, S., & Shih, L. C. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.02.011 · Cited by 20
Pérez‐Grijalba, V., Pesini, P., Allué, J. A., Sarasa, L., Montañés, M., Lacosta, A.-M., Casabona, D., José, I. S., Boada, M., Tárraga, L., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140156 · Cited by 20
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
Application of the IWG-2 Diagnostic Criteria for Alzheimer’s Disease to the ADNI
Wang, H.-F., Initiative, A. A. D. N., Tan, L., Cao, L., Zhu, X., Jiang, T., Tan, M., Liu, Y., Wang, C., Tsai, R. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150824 · Cited by 18
Uchida, Y., Nishimaki, K., Soldan, A., Pettigrew, C. A., Ho, S. G., Moghekar, A., Wang, M., Miller, M. I., Albert, M., & Oishi, K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70544 · Cited by 17
Scarth, M., Rissanen, I. L., Scholten, R. J. P. M., & Geerlings, M. I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210218 · Cited by 18
The association of serum uric acid with cognitive impairment and ATN biomarkers
Huang, S., Wang, J., Fan, D., Luo, T., Li, Y., Tu, Y., Shen, Y., Zeng, G., Chen, D., Wang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.943380 · Cited by 17
Gonzalez, J., Wilson, A. M., Byrd, D., Cortes, E. P., Crary, J. F., & Morgello, S. (2023) · AIDS · doi:10.1097/qad.0000000000003556 · Cited by 17
Emerging Biomarkers in Cognition
Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 17
Self-citationLim, J., Park, Y. H., Jang, J., Park, S. Y., Kim, S., & Initiative, A. D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091400 · Cited by 17
Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment
Huart, C., Rombaux, P., Gérard, T., Hanseeuw, B. J., Lhommel, R., Quenon, L., Ivanoiu, A., & Mouraux, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141494 · Cited by 20
Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
Pouclet‐Courtemanche, H., Nguyen, T., Skrobala, E., Boutoleau‐Bretonnière, C., Pasquier, F., Bouaziz-Amar, É., Bigot‐Corbel, E., Schraen‐Maschke, S., Dumurgier, J., Paquet, C., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.001 · Cited by 18
Villeneuve, S.-C., Houot, M., Cacciamani, F., Verrijp, M., Dubois, B., Sikkes, S. A. M., Epelbaum, S., MEMENTO study group and the INSIGHT‐preAD study group, Bakardjian, H., Benali, H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.08.009 · Cited by 17
Li, Z., Li, K., Luo, X., Zeng, Q., Zhao, S., Zhang, B., Zhang, M., Chen, Y., & Initiative, A. D. N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.550664 · Cited by 17
Brain investigation and brain conceptualization.
Redolfi, A., Bosco, P., Manset, D., & Frisoni, G. B. (2013) · Europe PMC (PubMed Central) · Cited by 17
The New Criteria for Alzheimer’s Disease - Implications for Geriatricians*
Molin, P., & Rockwood, K. J. (2016) · Canadian Geriatrics Journal · doi:10.5770/cgj.19.207 · Cited by 22
Alzheimer's disease/dementia-associated brain pathology in aging DPP6-KO mice
Lin, L., Petralia, R. S., Holtzclaw, L. A., Wang, Y., Abebe, D. T., & Hoffman, D. A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105887 · Cited by 17
Łuczkowski, M. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.03.001 · Cited by 17
Brier, M. R., McCarthy, J. E., Benzinger, T. L. S., Stern, A., Su, Y., Friedrichsen, K. A., Morris, J. C., Ances, B. M., & Vlassenko, A. G. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.025 · Cited by 16
Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
McCollum, L., Das, S. R., Xie, L., de Florès, R., Wang, J., Xie, S. X., Wisse, L. E. M., Yushkevich, P. A., & Wolk, D. A. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102717 · Cited by 15
Cerebrovascular disease in suspected non‐Alzheimer's pathophysiology and cognitive decline over time
Saridin, F. N., Chew, K. A., Reilhac, A., Gyanwali, B., Villaraza, S. G., Tanaka, T., Scheltens, P., van der Flier, W. M., Chen, C., & Hilal, S. (2022) · European Journal of Neurology · doi:10.1111/ene.15337 · Cited by 15
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. A. (2012) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15
Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers
Roberts, R. O., Knopman, D. S., Syrjanen, J. A., Aakre, J. A., Vassilaki, M. E., Kremers, W. K., Mielke, M. M., Machulda, M. M., Graff‐Radford, J., Geda, Y. E., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004652 · Cited by 15
Self-citationBock, J. R., Russell, J., Hara, J., & Fortier, D. (2021) · Frontiers in Digital Health · doi:10.3389/fdgth.2021.750549 · Cited by 17
Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease
Alexopoulos, P., Roesler, J., Thierjung, N., Werle, L., Buck, D., Yakushev, I. Y., Gleixner, L. S., Kagerbauer, S. M., Ortner, M., Grimmer, T., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0628-7 · Cited by 17
Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration
Santana, I. J., Baldeiras, I., Santiago, B., Duro, D., Freitas, S., Tábuas‐Pereira, M., Almeida, M. R., & Oliveira, C. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179908 · Cited by 15
Huang, Q., Cao, X., Chai, X., Wang, X., Xu, L., & Xiao, C. (2019) · Medicine · doi:10.1097/md.0000000000015972 · Cited by 15
Huang, S., Ma, Y., Bi, Y., Shen, X., Hou, X., Cao, X., Ou, Y., Zhao, B. T., Dong, Q., Tan, L., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15306 · Cited by 15
Li, Q., Hu, H., Zhang, G.-W., Hu, H., Ou, Y., Huang, L., Wang, A.-Y., Gao, P., Ma, L., Tan, L., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01396-w · Cited by 15
Dyrba, M., Initiative, A. D. N., Grothe, M. J., Mohammadi, R., Binder, H., Kirste, T., & Teipel, S. J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161197 · Cited by 15
Hohman, T. J., Dumitrescu, L. C., Oksol, A., Wagener, M. A., Gifford, K. A., Jefferson, A. L., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188501 · Cited by 15
Brain Atrophy on Magnetic Resonance Imaging as a Biomarker of Neurodegeneration
Jack, C. R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2843 · Cited by 15
Self-citationAnti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer’s Disease
Gomar, J. J., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150937 · Cited by 13
Lan, G., Du, J., Chen, X., Wang, Q., Han, Y., & Guo, T. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.09.012 · Cited by 15
Insights into cognitive aging and Alzheimer’s disease using amyloid PET and structural MRI scans
Duara, R., Barker, W., Loewenstein, D., Greig, M. T., Rodriguez, R. A., Goryawala, M., Zhou, Q., & Adjouadi, M. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0110-6 · Cited by 15
Fibrillar amyloid correlates of preclinical cognitive decline
Stonnington, C. M., Chen, K., Lee, W., Locke, D. E. C., Dueck, A. C., Liu, X., Roontiva, A., Fleisher, A., Caselli, R. J., & Reiman, E. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.009 · Cited by 13
Byun, M. S., Kim, H. J., Yi, D., Choi, H. J., Baek, H., Lee, J. H., Choe, Y. M., Lee, S. H., Ko, K., Sohn, B. K., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101765 · Cited by 13
Shen, X., Kuo, K., Yang, Y., Li, H., Chen, S., Cui, M., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12198 · Cited by 13
Lagarde, J., Olivieri, P., Tonietto, M., Gervais, P., Comtat, C., Caillé, F., Bottlaender, M., & Sarazin, M. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01628-9 · Cited by 17
Ren, S., Pan, Y., Li, J., Huang, L., Cui, L., Jiang, D., Huang, Q., Guan, Y., Guo, Q., Shen, D. G., et al. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20220080 · Cited by 13
Biological Factors Contributing to the Response to Cognitive Training in Mild Cognitive Impairment
Peter, J., Schumacher, L. V., Landerer, V., Abdulkadir, A., Kaller, C. P., Lahr, J., & Klöppel, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170580 · Cited by 13
Wong, B. Y. X., Yong, T. T., Lim, L., Tan, J. Y., Ng, A. S. L., Ting, S. K. S., Hameed, S., Ng, K. P., Zhou, J. H., & Kandiah, N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181261 · Cited by 13
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-04-09
- Volume
- 71
- Issue
- 6
- Pages
- 765-775
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3586223
- OpenAlex
- W2044429455
- Cited by
- 602
- References
- 71
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 21 · 2023: 28 · 2022: 29 · 2021: 40 · 2020: 33 · 2019: 40 · 2018: 44 · 2017: 60 · 2016: 80 · 2015: 65 · 2014: 63 · 2013: 51 · 2012: 10
- FWCI
- 27.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- National Institute on Aging (R01AG11378, P50‐AG16574, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Center for Research Resources (C06RR018898)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- preclinical Alzheimer's disease, NIA-AA criteria, Pittsburgh compound B PET, cerebral amyloidosis, FDG-PET, hippocampal volume, neurodegeneration biomarkers, cognitively normal older adults, diagnostic classification
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Brain, Cognition Disorders, Female, Humans, Longitudinal Studies, Male, Mental Status Schedule, Neuropsychological Tests, Thiazoles, United States, Biomarkers, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
